Avacta selects chemotherapy drug candidate for pre-clinical development
Avacta Group announced that the chemotherapy candidate AVA3996 will be…
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.